Skip to main content
OpenTrials
Completed

NCT Number: NCT04826718

SARS-CoV-2/COVID-19 Infection Among Health Care Workers

The present study finds opportunities and justifications, taking into consideration that the nature of professional practice in health needs scientific evidence resulting from systematic and systemic studies to strengthen the basis for the decisions made to have an impact on various levels, from the patient to health management itself. In addition, Cabo Verdean authorities may benefit from new evidence obtained by this study. It intends, in a growing number of health professionals exposed or infected with SARS-CoV-2, in the different health structures of the country, to contribute to substantiate a better perception of the problem and the required solutions. Therefore, assessing the potential risk factors for SARS-CoV-2 infection among healthcare workers will be essential to characterize virus transmission, preventing future infections in them and providing the associated healthcare. Due to the advances and important changes described, questions arise that guide this research and allow us to identify the problem.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SARS-CoV-2 BCG COVID-19 Coronaviridae Infections Coronavirus Infections Health Care Worker Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universidade de Cabo Verde

Praia, Santiago, 379C, Cabo Verde

About this study

The problem is stated in the following starting questions:

What conditions and factors are associated with infection and non-infection by SARS-CoV-2 among health professionals working in the three hospitals on the islands of Santiago and São Vicente? Which are they (gender, age group, profession, type of contact, etc.)? Where do the infected HCW typically work (sector)? When and how did the infection occur? What is the prevalence of SARS-CoV-2 antibody in professionals with confirmed SARS-CoV-2 infection and in HCW that thought they were not infected by SARS-CoV-2? How long do anti-SARS-CoV-2 antibodies last? What is the impact of infection on unplanned absenteeism? Which symptoms and complaints (if any) persists after SARS-CoV-2 infection?

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Being a healthcare professional working in one of the hospitals where the study will take place
  • Be aged ≥18 years;
  • Cases: SARS-CoV-2 infection confirmed by PCR test and/or Rapid Antigen Test;
  • Control: No evidence and/or record of past infection with SARS-CoV-2.

Exclusion criteria

  • Case: Confirmation of diagnosis test for SARS-CoV-2 without indication of specimen collection date.
  • Control: Suspected SARS-CoV-2 infection.

Treatment and study plan

Questionaire

Other

A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.

Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).

Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls).

Other names: SARS-CoV-2 Serology (POC Test), SARS-CoV-2 Serology (ELISA Test)

Primary outcomes

  1. Total number of days absent from work due to COVID-19

    Time frame: From March 2020 to March 2022

    Absenteeism due to COVID-19 related symptoms

  2. Unplanned Absenteeism

    Time frame: 6 months after inclusion

    Unplanned absenteeism following SARS-CoV-2 infection

  3. Symptomatology after infection by SARS-CoV-2

    Time frame: 6 months after inclusion

    If have or not any symptomes after SARS-CoV-2 infection

  4. Presence or absence of anti-SARS-CoV-2 Acs

    Time frame: 6 months after inclusion

    Presence or not of anti-SARS-CoV-2 Anti-N and anti-S

  5. Duration of anti-SARS-CoV-2 Acs

    Time frame: After infection

    Time of duration of anti-SARS-CoV-2 Anti-N and anti-S

Sponsors and collaborators

Lead sponsor

Universidade de Cabo Verde

Other

Collaborators

  • Bandim Health Project, Bissau, Guinea-Bissau
  • Centro de Investigacao em Saude de Manhica
  • European and Developing Countries Clinical Trials Partnership (EDCTP)
  • Institute of Hygiene and Tropical Medicine, NOVA University, Lisbon, Portugal
  • National Institute of Public Health of Cape Verde, Praia, Cape Verde
  • University of Southern Denmark

Registry information

Official study title

Associated Factors in the Transmission and Dynamics of SARS-CoV-2 Infection Among Health Care Workers in Hospitals on the Islands of Santiago and São Vicente in Cabo Verde

Important dates

Study start
2021
Primary completion
2021
Study completion
2023
First posted
Apr 1, 2021
Registry last updated
Jun 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.